Clexio Biosciences Ltd.   Report issue

For profit Phase 2
Founded: Petach Tikva Israel (2018)

Organization Overview

First Clinical Trial
2019
NCT04103892
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Clexio Biosciences Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

esketamine (spravato) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1